Opendata, web and dolomites

MBLIs SIGNED

New Approaches to Metallo-β-Lactamase Inhibitors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MBLIs project word cloud

Explore the words cloud of the MBLIs project. It provides you a very rough idea of what is the project "MBLIs" about.

relevance    denaturing    clear    almost    generation    acids    structurally    screening    bacterial    dcc    obtain    healthcare    breadth    molecules    organic    antibiotics    variations    billion    biology    active    global    die    penicillin    inhibitors    threat    sbl    mblis    medicinal    clinical    pathogens    inhibited    lactamases    metallo    resistant    biological    selectivity    public    inhibition    mbl    pbps    combination    occurrence    little    sites    alarming    antibiotic    clinically    human    mechanistically    serious    desired    utility    ms    representing    society    bla    caused    lactam    interdisciplinary    representative    25    critical    small    binding    unlike    efficacy    rendering    resistance    blas    therapies    pioneer    hydrolysis    structures    60    serine    inspire    declining    compounds    gt    patients    chemistry    directed    mbli    esi    broad    contain    health    spectrum    mechanism    situation    modified    panel    enzymes    structural    least    mechanisms    protein    dcls    synthesis    phosphinic    inactive    nmr    catalyse    spends    unrelated    ring    beta    coupled    reporter    phosphonates    mbls    infections    31p    equilibrated   

Project "MBLIs" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://schofield.chem.ox.ac.uk/mariosmarkoulides.aspx
 Total cost 183˙454 €
 EC max contribution 183˙454 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2017-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 183˙454.00

Map

 Project objective

The increasing problem of antibiotic resistance is a major global public health concern. In the EU 25,000 patients die each year due to infections caused by multi-resistant bacterial pathogens, and the EU spends at least 1.5 billion euro per year on healthcare costs. The β-lactam antibiotics are the most important antibiotics representing >60% of small molecules in clinical use. BLAs contain a β-lactam ring which is critical for penicillin-binding protein inhibition. However, BLA efficacy is declining due to resistance mechanisms including the widespread occurrence of β-lactamases, which catalyse β-lactam hydrolysis. Metallo-β-lactamases, long-considered as of little clinical relevance, now present a serious global threat to almost all BLAs, rendering the development of approaches to MBL inhibitors important. Unlike the serine β-lactamases, the MBLs are structurally and mechanistically unrelated to PBPs, and are not inhibited by current mechanism-based SBL inhibitors. Due to variations in MBL structures, a major challenge in MBL inhibition is the development of compounds with the breadth of selectivity necessary for clinical utility. Society is now in an alarming situation and there is a clear need for the development of an MBLI:β-lactam-based combination therapies. The aim of my proposed work is to pioneer, enable and inspire the generation of broad-spectrum MBLIs active against a panel of clinically representative MBLs, but inactive against human enzymes with related active sites. To obtain the desired objective, novel approaches are proposed and include the use of phosphonates and phosphinic acids for: (a) MBL-directed DCC coupled to analysis by non-denaturing ESI-MS and 31P-NMR, (b) 31P-NMR reporter screening method, (c) pre-equilibrated DCLs for MBL-directed DCC, and (d) the synthesis of modified inhibitors. The study will be interdisciplinary and encompass organic synthesis, biological MS/NMR, structural biology, and medicinal chemistry.

 Publications

year authors and title journal last update
List of publications.
2016 David Yuxin Wang, Martine I Abboud, Marios S Markoulides, Jürgen Brem, Christopher J Schofield
The road to avibactam: the first clinically useful non-β-lactam working somewhat like a β-lactam
published pages: 1063-1084, ISSN: 1756-8919, DOI: 10.4155/fmc-2016-0078
Future Medicinal Chemistry 8/10 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MBLIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MBLIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

BIOplasma (2019)

Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Read More  

CIRICC (2019)

Complicity: Individual Responsibility in Collective Contexts

Read More